Lunesta Side Effects
The most common side effects of Lunesta (eszopiclone) are unpleasant/metallic taste (occurring in 17-26% of patients), followed by dry mouth, drowsiness/somnolence, dizziness, and headache, with the unpleasant taste being the only side effect consistently elevated above placebo across all studies. 1
Common Side Effects (Occurring in Clinical Trials)
Based on FDA labeling and clinical practice guidelines, the following adverse effects occur with Lunesta:
Most Frequent Side Effects:
- Unpleasant/metallic taste: 17.6-26.1% (vs 0.5-5.6% placebo) - this is the most distinctive and common side effect 2
- Dry mouth: 4-6.6% (vs 1.4-1.5% placebo) 2
- Somnolence/drowsiness: 8.8-9.1% (vs 2.6-3.2% placebo) 2
- Dizziness: 9.8% (vs 3.1% placebo) 2
- Headache: No significant difference from placebo 2
- Common cold symptoms 1
Additional Side Effects at 3mg Dose:
- Myalgia (muscle pain): 6.0% (vs 2.9% placebo) 2
Important clinical note: The 2mg dose showed essentially no difference from placebo for dizziness, headache, and next-day somnolence in meta-analyses, with only unpleasant taste and minimal dry mouth elevation being statistically significant. 2
Serious Side Effects (Requiring Immediate Medical Attention)
The FDA medication guide emphasizes these potentially dangerous adverse events 1:
Complex Sleep Behaviors (Black Box Warning):
- Sleep-driving and other activities while not fully awake
- Making and eating food unconsciously
- Talking on the phone
- Having sex
- Sleep-walking
Risk increases with: alcohol consumption, concurrent CNS depressants, or doses exceeding recommendations 1
Psychiatric and Neurological Effects:
- Abnormal thoughts and behavior: more outgoing or aggressive behavior than normal, confusion, agitation
- Hallucinations
- Worsening of depression and suicidal thoughts or actions
- Memory loss (amnesia) - particularly at doses ≥6mg 3
- Anxiety 1
Severe Allergic Reactions:
- Swelling of tongue or throat
- Trouble breathing
- Nausea and vomiting 1
Next-Day Impairment
You may still feel drowsy the next day after taking Lunesta - the FDA explicitly warns against driving or performing dangerous activities until fully awake. 1 However, objective testing showed no impairment in braking reaction time or digit symbol substitution at either 2mg or 3mg doses. 2
Long-Term Safety Concerns
The 2016 American College of Physicians guideline noted that observational studies (not randomized trials) suggested hypnotic use for insomnia was associated with:
- Increased risk for dementia
- Increased risk for fractures
- Increased risk for major injury 3
Critical caveat: These associations come from observational data with potential confounding, not from the controlled trials themselves, which showed insufficient evidence for most harms. 3
Withdrawal and Discontinuation Effects
Following discontinuation, the following withdrawal symptoms may occur (reported at ≤2% incidence):
- Anxiety
- Abnormal dreams
- Nausea and upset stomach 1
One study showed rebound insomnia with the 2mg dose in non-elderly subjects after discontinuation, though no significant rebound was seen for sleep onset latency or wake after sleep onset in the first three nights post-discontinuation. 3, 4
Abuse and Dependence Potential
Lunesta is a Schedule IV controlled substance with potential for abuse and dependence. 1 At doses of 6-12mg (2-4 times the maximum recommended dose), eszopiclone produced euphoric effects similar to diazepam 20mg in individuals with histories of benzodiazepine abuse, along with dose-related increases in amnesia and hallucinations. 1
Special Population Considerations
Elderly Patients:
The most common side effects in elderly patients are:
- Unpleasant taste
- Dry mouth
- Dizziness
- Somnolence 5
The elimination half-life increases from 6 hours to approximately 9 hours in patients ≥65 years, requiring dose adjustment. 4
Patients with Liver Disease:
One case report documented acute liver injury in a patient with chronic hepatitis B after eszopiclone treatment, with rapid transaminase elevation that resolved upon discontinuation. 6 While hepatitis and liver injury are listed as rare adverse reactions, patients with chronic liver disease may have altered drug detoxification and increased toxicity risk.
Cognitive and Motor Function
No significant impairment was demonstrated in:
However, the FDA documents note that most pharmacotherapies for insomnia carry risks for cognitive and behavioral changes, including driving impairment. 3
Tolerance Development
No tolerance developed to sleep efficacy parameters over 6 months of continuous use in clinical trials, and no significant changes were seen on the Benzodiazepine Withdrawal Scale following discontinuation. 2, 1, 4
Overall Safety Profile
The 2017 American Academy of Sleep Medicine guideline concluded there was "limited or no consistent evidence of adverse events in excess of placebo, with the possible exception of unpleasant taste," and that benefits marginally outweigh harms. 2 The overall quality of evidence for harms was rated as very low to moderate due to short trial durations, industry sponsorship, and potential publication bias. 2